Johnson & Johnson Business Continuity Statement (9/23)
In our role as a global health leader, Johnson & Johnson is closely monitoring the COVID-19 (coronavirus) pandemic and taking steps to help prevent the spread of the virus as well as exploring the potential for a vaccine.
We have robust business continuity plans in place across our global supply chain network to prepare for unforeseen events and to meet the needs of the patients, customers and consumers who depend on our products. These steps include maintaining critical inventory at major distribution centers away from high-risk areas and working with external suppliers to support our preparedness plans.
The need for increased restrictions in some countries to help address the spread of the virus is presenting global supply chains with unprecedented logistical challenges; however, we are working closely with suppliers, distributors, local governments and regulators to continue to meet patient, customer and consumer need. We are closely monitoring product demand and supply levels across our global network to ensure adequate and effective distribution, and working to minimize delivery disruption to our customers who depend on us for timely delivery. We are also advising private and public customers to maintain normal ordering patterns where possible to avoid service delays, especially for those who rely on our critical medicines.
Below is a summary by sector:
- Pharmaceutical: While this remains a dynamic situation, we do not foresee pharmaceutical supply interruptions related to COVID-19 at this time.
- Medical Devices: While this remains a dynamic situation, we are not experiencing significant product supply interruptions related to COVID-19 at this time.
- Consumer: We are experiencing increased consumer-driven demand with certain products and markets, which we are currently meeting in a controlled manner. We are taking all possible measures to maximize product availability.
As a leader in global health, our top priority remains our patients, customers and employees. We are partnering with global and local health authorities to address immediate and long-term health care needs, to ensure sustainable supply of our critical medicines, as well as to research potential vaccines and therapeutics.
We will remain on the front lines of this health crisis, bringing our full resources and minds to combat it.